RS55181B1 - Farmaceutske kompozicije sa rezistencijom na rastvorljivi cea - Google Patents

Farmaceutske kompozicije sa rezistencijom na rastvorljivi cea

Info

Publication number
RS55181B1
RS55181B1 RS20160791A RSP20160791A RS55181B1 RS 55181 B1 RS55181 B1 RS 55181B1 RS 20160791 A RS20160791 A RS 20160791A RS P20160791 A RSP20160791 A RS P20160791A RS 55181 B1 RS55181 B1 RS 55181B1
Authority
RS
Serbia
Prior art keywords
seq
cea
amino acid
acid sequence
human
Prior art date
Application number
RS20160791A
Other languages
English (en)
Serbian (sr)
Inventor
Ralf LUTTERBÜSE
Petra Mayer
Evelyne Schaller
Doris Rau
Susanne Mangold
Peter Kufer
Alexander Murr
Monika Wissinger
Tobias Raum
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of RS55181B1 publication Critical patent/RS55181B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)
RS20160791A 2005-12-21 2006-12-21 Farmaceutske kompozicije sa rezistencijom na rastvorljivi cea RS55181B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75196305P 2005-12-21 2005-12-21
EP05028064 2005-12-21
US78086106P 2006-03-10 2006-03-10
PCT/EP2006/012425 WO2007071426A1 (en) 2005-12-21 2006-12-21 Pharmaceutical compositions with resistance to soluble cea
EP06841112.3A EP1976880B1 (en) 2005-12-21 2006-12-21 Pharmaceutical compositions with resistance to soluble cea

Publications (1)

Publication Number Publication Date
RS55181B1 true RS55181B1 (sr) 2017-01-31

Family

ID=40413962

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160791A RS55181B1 (sr) 2005-12-21 2006-12-21 Farmaceutske kompozicije sa rezistencijom na rastvorljivi cea

Country Status (24)

Country Link
US (3) US8394926B2 (OSRAM)
EP (2) EP2527370A1 (OSRAM)
JP (2) JP5399712B2 (OSRAM)
KR (1) KR101287777B1 (OSRAM)
CN (1) CN101370827B (OSRAM)
AU (1) AU2006328886C1 (OSRAM)
BR (1) BRPI0620632A2 (OSRAM)
CA (1) CA2633766C (OSRAM)
CY (1) CY1118053T1 (OSRAM)
DK (1) DK1976880T3 (OSRAM)
ES (1) ES2595091T3 (OSRAM)
HR (1) HRP20161216T1 (OSRAM)
HU (1) HUE031151T2 (OSRAM)
IL (1) IL192277A (OSRAM)
LT (1) LT1976880T (OSRAM)
ME (1) ME02581B (OSRAM)
NZ (1) NZ569204A (OSRAM)
PL (1) PL1976880T3 (OSRAM)
PT (1) PT1976880T (OSRAM)
RS (1) RS55181B1 (OSRAM)
RU (2) RU2426743C2 (OSRAM)
SG (1) SG193141A1 (OSRAM)
WO (1) WO2007071426A1 (OSRAM)
ZA (1) ZA200805400B (OSRAM)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
AU2006328882B2 (en) * 2005-12-21 2011-06-16 Amgen Research (Munich) Gmbh Pharmaceutical antibody compositions with resistance to soluble CEA
PL1976880T3 (pl) * 2005-12-21 2017-01-31 Amgen Research (Munich) Gmbh Kompozycje farmaceutyczne odporne na rozpuszczalny cea
MX2009011523A (es) 2007-04-27 2009-11-09 Dow Global Technologies Inc Metodo para clasificar rapidamente huespedes microbianos para identificar ciertas cepas con rendimiento y/o calidad mejorados en la expresion de proteinas heterologas.
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
CN102482701B (zh) * 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
CA2782330A1 (en) * 2009-12-01 2011-06-09 Medimmune, Llc Improved methods and compositions for detecting and treating cea-expressing cancers
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
US20140242081A1 (en) * 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
WO2013054320A1 (en) * 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013162748A1 (en) * 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
HK1209434A1 (en) 2012-11-13 2016-04-01 Astellas Pharma Inc. Agents for treatment of claudin expressing cancer diseases
CA2889962C (en) 2012-11-20 2023-10-24 Sanofi Anti-ceacam5 antibodies and uses thereof
PT2961771T (pt) * 2013-02-26 2020-02-28 Roche Glycart Ag Moléculas de ligação ao antigénio biespecíficas para ativação das células t, específicas para cd3 e cea
CN105143270B (zh) 2013-02-26 2019-11-12 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
UY35484A (es) 2013-03-15 2014-10-31 Amgen Res Munich Gmbh Molécula de unión de cadena simple que comprenden ABP de extremo N
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
KR102452349B1 (ko) 2014-04-27 2022-10-11 페임웨이브 리미티드 Ceacam1에 대한 인간화 항체
EP3164417A1 (en) 2014-07-01 2017-05-10 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
US10563194B2 (en) 2015-02-24 2020-02-18 BioAlta, LLC Conditionally active biological proteins
CN106432502B (zh) * 2015-08-10 2020-10-27 中山大学 用于治疗cea阳性表达肿瘤的双特异纳米抗体
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MA43025A (fr) 2015-10-02 2021-05-26 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3
EP4026848A1 (en) 2015-12-09 2022-07-13 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing the cytokine release syndrome
AU2017205089B2 (en) * 2016-01-08 2023-10-05 F. Hoffmann-La Roche Ag Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
EP3464380B1 (en) 2016-06-02 2024-11-06 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
CN107663240B (zh) 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
AU2017380981B2 (en) 2016-12-19 2025-01-30 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1BB (CD137) agonists
BR112019013189A2 (pt) 2017-01-03 2019-12-10 Hoffmann La Roche moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa
CN107056952A (zh) * 2017-05-10 2017-08-18 常州市第人民医院 Cea.car‑t及其制备与应用
CN107058234B (zh) * 2017-05-12 2019-09-13 常州市第一人民医院 Car.il-33-t及其制备与应用
WO2019028125A1 (en) 2017-08-01 2019-02-07 Ab Studio Inc. Bispecific antibodies and uses thereof
BR112020007630A2 (pt) 2017-11-01 2020-11-17 F. Hoffmann-La Roche Ag anticorpo biespecífico ox40, produto farmacêutico, composição farmacêutica e anticorpos biespecíficos anti-fap/ anti-ox40
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
US11555071B2 (en) 2018-06-03 2023-01-17 Lamkap Bio Beta Ltd. Bispecific antibodies against CEACAM5 and CD47
TW202035447A (zh) 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 新穎雙特異性促效性4-1bb抗原結合分子
PE20211696A1 (es) 2018-12-21 2021-09-01 Hoffmann La Roche Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor
CN113660956B (zh) 2019-01-28 2024-10-29 Ab诊疗公司 双特异性抗体及其用途
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
KR20210124260A (ko) 2019-02-07 2021-10-14 사노피 폐암을 치료하기 위한 항-ceacam5 면역접합체의 용도
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2020291014B2 (en) 2019-06-13 2025-06-05 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
JP7354306B2 (ja) * 2019-06-27 2023-10-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
WO2021041300A2 (en) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
EP4025254A1 (en) 2019-09-03 2022-07-13 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
KR20220113353A (ko) 2019-09-18 2022-08-12 람캅 바이오 알파 에이지 Ceacam5 및 cd3에 대한 이중특이적 항체
EP4038053A1 (en) 2019-09-30 2022-08-10 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
CA3155077A1 (en) 2019-10-25 2021-04-29 Romas Kudirka Thienoazepine immunoconjugates, and uses thereof
TW202128765A (zh) * 2019-11-21 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種雙特異性抗體
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
WO2021226440A1 (en) 2020-05-08 2021-11-11 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
MX2023001679A (es) 2020-08-13 2023-02-22 Bolt Biotherapeutics Inc Inmunoconjugados de pirazolazepina y usos de estos.
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
CA3200051A1 (en) 2020-12-11 2022-06-16 Shelley Erin ACKERMAN Anti-cea immunoconjugates, and uses thereof
JP2024501809A (ja) 2020-12-18 2024-01-16 ランカプ バイオ ベータ リミテッド Ｃｅａｃａｍ５およびｃｄ４７に対する二重特異性抗体
AU2022245340A1 (en) 2021-03-26 2023-11-09 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
CA3212926A1 (en) 2021-03-26 2022-09-29 Gary Brandt 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
AU2023237620A1 (en) 2022-03-23 2024-08-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
KR20250025384A (ko) 2022-06-16 2025-02-21 람카프 바이오 베타 엘티디. Ceacam5 및 cd47에 대한 이중특이적 항체 및 ceacam5 및 cd3에 대한 이중특이적 항체의 조합 요법
WO2024192308A2 (en) 2023-03-14 2024-09-19 Xencor, Inc. Anti-cd28 compositions
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1992010755A1 (en) 1990-12-05 1992-06-25 Novo Nordisk A/S Proteins with changed epitopes and methods for the production thereof
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
EP0833907A1 (en) 1995-06-23 1998-04-08 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
JP4169478B2 (ja) 1998-04-21 2008-10-22 マイクロメット アーゲー Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
CA2438628A1 (en) 2001-02-19 2002-08-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Artificial proteins with reduced immunogenicity
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7820166B2 (en) * 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
PL1976880T3 (pl) 2005-12-21 2017-01-31 Amgen Research (Munich) Gmbh Kompozycje farmaceutyczne odporne na rozpuszczalny cea
AU2006328882B2 (en) * 2005-12-21 2011-06-16 Amgen Research (Munich) Gmbh Pharmaceutical antibody compositions with resistance to soluble CEA

Also Published As

Publication number Publication date
HK1115890A1 (zh) 2008-12-12
AU2006328886C1 (en) 2011-11-17
CN101370827A (zh) 2009-02-18
RU2008129787A (ru) 2010-01-27
JP5399712B2 (ja) 2014-01-29
JP2013056885A (ja) 2013-03-28
US9982063B2 (en) 2018-05-29
LT1976880T (lt) 2016-10-10
KR101287777B1 (ko) 2013-07-23
CY1118053T1 (el) 2017-06-28
NZ569204A (en) 2012-03-30
EP1976880B1 (en) 2016-07-06
SG193141A1 (en) 2013-09-30
ME02581B (me) 2017-06-20
IL192277A (en) 2016-08-31
KR20080079330A (ko) 2008-08-29
RU2010148652A (ru) 2012-06-10
IL192277A0 (en) 2008-12-29
WO2007071426A1 (en) 2007-06-28
RU2426743C2 (ru) 2011-08-20
CN101370827B (zh) 2015-10-14
BRPI0620632A2 (pt) 2011-12-20
RU2573893C2 (ru) 2016-01-27
US20170137538A1 (en) 2017-05-18
CA2633766C (en) 2016-06-28
CA2633766A1 (en) 2007-06-28
US8394926B2 (en) 2013-03-12
PL1976880T3 (pl) 2017-01-31
HRP20161216T1 (hr) 2016-11-18
PT1976880T (pt) 2016-09-28
ES2595091T3 (es) 2016-12-27
JP2009520734A (ja) 2009-05-28
ZA200805400B (en) 2009-09-30
DK1976880T3 (en) 2016-09-26
HUE031151T2 (en) 2017-06-28
AU2006328886A1 (en) 2007-06-28
AU2006328886B2 (en) 2011-04-14
US9695250B2 (en) 2017-07-04
US20130273050A1 (en) 2013-10-17
US20090226432A1 (en) 2009-09-10
EP1976880A1 (en) 2008-10-08
EP2527370A1 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
US9982063B2 (en) Pharmaceutical compositions with resistance to soluble CEA
US8901278B2 (en) Pharmaceutical antibody compositions with resistance to soluble CEA
JP2022516505A (ja) 癌および他の疾患の治療のための、クローディン１８．２に特異的な結合分子、その組成物および方法
CA3186574A1 (en) Anti-human neurotensin receptor 1 antibody and use thereof
AU2011204778B2 (en) Pharmaceutical compositions with resistance to soluble CEA
HK1115890B (en) Pharmaceutical compositions with resistance to soluble cea
HK1178548A (en) Compounds having resistance to soluble cea
EP3619237A1 (en) Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis
NZ569144A (en) Pharmaceutical antibody compositions with resistance to soluble CEA - comprising IgG1antibodies that bind to CEA